In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
doctor

EXPERT PERSPECTIVES

A New Foundation for Designing Winning Brand Strategies – The Patient Journey Re-envisioned
The years immediately preceding a pharmaceutical product launch are arguably one of the riskiest periods in business and “getting it right” has never been more essential. IMS experts discuss the importance of the patient journey – a powerful framework for understanding the market and patient experience – in driving brand growth.

 

LATEST THINKING

Achieving Launch Excellence in Oncology: Four key drivers marketers need to consider for oncology launch planning.

Balancing Act – Aligning Competing Strategies: How to harmonize efforts across new commercial model and launch excellence initiatives.

IMS Asia-Pacific Insight: The heated price-volume debate mounts in Asia.

Career

Supercharge your career in life sciences consulting.

 

Our insights are your competitive advantage.

IMS Consulting Group is the world’s leading, specialized advisor on critical business issues in life sciences.

With a global presence and local expertise across five continents, we know the pulse of the market – anticipating change, understanding its impact and resolving the challenges it brings. From pricing and market access and marketing issues to product, portfolio and geographic investment decisions – our life sciences consulting teams offer insights that drive results. All backed by the strongest evidence and analytics.

Brand & Commercial Strategy

Pharma growth rates will be the lowest ever through 2014. What questions should you address?

Geographic Investments

By 2014, pharmerging markets will drive 50% of global growth. How can you harness their potential?

Health Economics & Outcomes Research

Real-world evidence is transforming the landscape. Are you capturing the outcomes that count?

Launch Excellence

Less than 1% of launches outperform. What does it take to be the best?

Pricing & Market Access

AMNOG has ended free pricing in Germany. What are the wider implications?


Strategy & Portfolio Analysis

Only 20% of medicines recoup the costs of development. How can you maximize return?